NCT02458014 2025-09-23
Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
9 trialsNCT04827745 2025-07-03
Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL
University of Maryland, Baltimore
Phase 2 Completed
NCT03367299 2025-01-22
LAL2317
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT03982992 2024-03-12
DLI-TARGET
Ludwig-Maximilians - University of Munich
Phase 2 Withdrawn
NCT04785547 2024-01-16
ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT
St. Anna Kinderkrebsforschung
Phase 2 Terminated
NCT03109093 2023-03-21
Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia
Goethe University
Phase 2 Completed
NCT04044560 2022-02-21
OZM-097
University of British Columbia
Phase 2 Terminated
NCT01207388 2020-02-10
BLAST
Amgen Research (Munich) GmbH
Phase 2 Completed
NCT00560794 2015-01-26
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen Research (Munich) GmbH
Phase 2 Completed